Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

Autor: Ulrika Jahn, Ulrike Garske-Román, Mattias Sandström, Mark Lubberink, Anders Sundin

Publikováno v: EJNMMI Research, Vol 13, Iss 1, Pp 1-9 (2023)

Abstract Background The accumulation of 177Lu-DOTATATE might be influenced by the amount of administered peptide in relation to the tumor somatostatin receptor expression. The effect of the administered peptide mass on the resulting absorbed dose in

Externí odkaz: https://doaj.org/article/32dff74e177348c5b1c53990a7ff6b8d

Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy

Autor: Judy S. Crabtree

Publikováno v: Frontiers in Endocrinology, Vol 8 (2017)

The molecular events leading to gastroenteropancreatic neuroendocrine tumor (GEP-NET) formation are largely unknown. Over the past decades, systemic chemotherapies have been replaced by therapies directed at particular molecular targets such as the s

Externí odkaz: https://doaj.org/article/46958ec636124dc6b454f39fa162a68b

Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT

Autor: Aline M. van der Loo–van der Schaaf, Elisabeth G.E. de Vries, Adrienne H. Brouwers, Annemiek M E Walenkamp, Ronald Boellaard, Johannes H. van Snick, Lotte D de Hosson

Publikováno v: de Hosson, L D, van der Loo-van der Schaaf, A M, Boellaard, R, van Snick, J H, de Vries, E G E, Brouwers, A H & Walenkamp, A M E 2019, ' Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT ', Clinical Nuclear Medicine, vol. 44, no. 8, pp. 612-619 . https://doi.org/10.1097/RLU.0000000000002640
Clinical Nuclear Medicine, 44(8), 612-619. LIPPINCOTT WILLIAMS & WILKINS
Clinical Nuclear Medicine, 44(8), 612-619. Lippincott Williams and Wilkins

Purpose Neuroendocrine tumors (NETs) can produce neuroendocrine amines resulting in symptoms. Selecting the most active amine-producing tumor lesions for local treatment might be beneficial for patients with metastatic small intestinal NET. Tumor bur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::796d685ef35abe6252e3e9def1ca6936
https://hdl.handle.net/11370/9e0a7de9-dafc-40f9-b850-3fa71ce86500

Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET)

Autor: Massimo Falconi, Stefano Partelli, Valentina Andreasi, Francesca Muffatti, Barbara Colombo, Angelo Corti, Marco F. Manzoni

Publikováno v: Pancreatology. 19:57-63

Background A reliable and accessible biomarker for nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET) is currently unavailable. Chromogranin A (CgA) represents the best-described neuroendocrine biomarker, but its accuracy is low. Vasostatin-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2616199e31696f524d1b772109ec0c61
https://doi.org/10.1016/j.pan.2018.11.005

Corrigendum to 'Fatal Systemic Vasoconstriction in a Case of Metastatic Small-Intestinal NET'

Autor: Konstantin Holzapfel, Jochen Stenzel, Sebastian Noe, Franziska Erlmeier, Florian Eyer

Publikováno v: Case Reports in Gastrointestinal Medicine, Vol 2017 (2017)
Case Reports in Gastrointestinal Medicine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::083e7d9f190f5a0409c6f6b86336cdd9
https://doaj.org/article/3bdf3014291b46dc86d448a4ee253dde